Trial reportJournal of neuro-oncology2020
Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms.
Trial report in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Psychological problems among cancer patients in relation to healthcare and societal costs: A systematic review.Psycho-oncology · 2021Pooled it
- Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).Journal of neuro-oncology · 2025Trial
- Telehealth group Cognitive-Behavioral Therapy for Insomnia (CBT-I) in primary brain tumor: Primary outcomes from a single-arm phase II feasibility and proof-of-concept trial.Neuro-oncology · 2024Trial
- eHealth cognitive rehabilitation for brain tumor patients: results of a randomized controlled trial.Journal of neuro-oncology · 2021Trial
- Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.Neuro-oncology practice · 2026Review
- Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma.Neuro-oncology practice · 2026Article
- Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility study.Neuro-oncology practice · 2026Article
- Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy.Contemporary clinical trials communications · 2026Article
- Early Palliative Care in Patients with Glioblastoma: Co-Design of an Integrated Care Pathway.Healthcare (Basel, Switzerland) · 2025Article
- Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.International journal of surgery (London, England) · 2025Article
- The impact of financial toxicity on quality of life for survivors of primary brain tumour.Journal of cancer survivorship : research and practice · 2025Article
- Article
- Reporting standards in randomized controlled trials involving neuro-oncology caregivers: A systematic review report from the RANO-Cares working group.Neuro-oncology practice · 2025Article
- Work-related experiences and unmet needs of patients with a malignant glioma and relevant professionals: the BrainWork study.Journal of cancer survivorship : research and practice · 2025Article
- But at What Cost? Healthcare Utilization of Canadian Carer-Employees.International journal of environmental research and public health · 2024Article
- Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.Current oncology reports · 2024Review
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- Association between viral infections and glioma risk: a two-sample bidirectional Mendelian randomization analysis.BMC medicine · 2023Article
- Association of Employment Status With Symptom Burden and Health-Related Quality of Life in People Living With Primary CNS Tumors.Neurology · 2023Observational
- Study protocol for Cognitive Behavioral Therapy for Insomnia in patients with primary brain tumor: A single-arm phase 2a proof-of-concept trial.Contemporary clinical trials communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundGliomas are associated with significant healthcare burden, yet reports of costs are scarce. While many costs are unavoidable there may be treatable symptoms contributing to higher costs. We describe healthcare and societal costs in glioma patients at high risk for depression and their family caregivers, and explore relationships between costs and treatable symptoms.
methodsData from a multicenter randomized trial on effects of internet-based therapy for depressive symptoms were used (NTR3223). Costs of self-reported healthcare utilization, medication use, and productivity loss were calculated for patients and caregivers separately. We used generalized linear regression models to predict costs with depressive symptoms, fatigue, cognitive complaints, tumor grade (low-/high-grade), disease status (stable or active/progression), and intervention (use/non-use) as predictors.
resultsMultiple assessments from baseline through 12 months from 91 glioma patients and 46 caregivers were used. Mean overall costs per year were M = €20,587.53 (sd = €30,910.53) for patients and M = €5,581.49 (sd = €13,102.82) for caregivers. In patients, higher healthcare utilization costs were associated with more depressive symptoms; higher medication costs were associated with active/progressive disease. In caregivers, higher overall costs were linked with increased caregiver fatigue, cognitive complaints, and lower patient tumor grade. Higher healthcare utilization costs were related to more cognitive complaints and lower tumor grade. More productivity loss costs were associated with increased fatigue (all P < 0.05).
conclusionsThere are substantial healthcare and societal costs for glioma patients and caregivers. Associations between costs and treatable psychological symptoms indicate that possibly, adequate support could decrease costs.
trial registrationNetherlands Trial Register NTR3223.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.